TrialBMJ open2026

TACE combined with apatinib versus TACE alone for unresectable hepatocellular carcinoma in China: a cost-effectiveness and budget impact analysis.

Yanxiao Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.